Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil Iontophoresis for Diabetic Foot Ulcers
NCT03654989Phase 2Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of treprostinil in diabetic foot ulcer (DFU) (3 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Percentage change of the wound area at 12 weeks. Started Jan 2020; status: terminated.
02
Drugs
treprostinil
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03654989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654989.